Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has signed an in-network provider agreement for its Target Selector liquid biopsy platform with Wellmark Blue Cross Blue Shield in Iowa and South Dakota.

This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.